Compare TransMedics Group Inc (TMDX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Xpeng Inc - ADR — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while Xpeng Inc - ADR trades at $9.91 (market cap $9.16B). The key difference: Xpeng Inc - ADR is far larger — about 3.3× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Xpeng Inc - ADR for 80 Days on average.
| TMDX | XPEV | |
|---|---|---|
Market Cap | $2.74B | $9.16B |
Volume | 949,331 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $150.42 | $28.07 |
52-Week Low | $61.99 | $9.25 |
Typical Hold Time | 24 Days | 80 Days |
Enterprise Value | $3.13B | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
XPeng (XPEV) trades at $9.90, up 3.34% with a bearish technical signal despite recent delivery growth. The company shows improving fundamentals with revenue surging to $76.72B in 2025 and narrowing losses, though it remains unprofitable with negative margins. Recent news highlights expansion into robotics and global vehicle launches, while analyst consensus remains bullish with a $17.55 price target representing 77% upside potential.
XPeng presents a high-risk, high-reward opportunity with strong revenue growth and technological innovation offset by persistent profitability challenges. The stock's current discount to analyst targets offers potential upside, but investors face risks from competitive pressures, execution challenges in new business lines, and ongoing losses that could pressure the balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
